These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. The Belgian trial with azithromycin for acute COPD exacerbations requiring hospitalization: an investigator-initiated study protocol for a multicenter, randomized, double-blind, placebo-controlled trial. Vermeersch K; Gabrovska M; Deslypere G; Demedts IK; Slabbynck H; Aumann J; Ninane V; Verleden GM; Troosters T; Bogaerts K; Brusselle GG; Janssens W Int J Chron Obstruct Pulmon Dis; 2016; 11():687-96. PubMed ID: 27099485 [TBL] [Abstract][Full Text] [Related]
4. Azithromycin maintenance treatment in patients with frequent exacerbations of chronic obstructive pulmonary disease (COLUMBUS): a randomised, double-blind, placebo-controlled trial. Uzun S; Djamin RS; Kluytmans JA; Mulder PG; van't Veer NE; Ermens AA; Pelle AJ; Hoogsteden HC; Aerts JG; van der Eerden MM Lancet Respir Med; 2014 May; 2(5):361-8. PubMed ID: 24746000 [TBL] [Abstract][Full Text] [Related]
5. Anti-IL-5 therapies for chronic obstructive pulmonary disease. Donovan T; Milan SJ; Wang R; Banchoff E; Bradley P; Crossingham I Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013432. PubMed ID: 33295032 [TBL] [Abstract][Full Text] [Related]
6. Blood eosinophil count and GOLD stage predict response to maintenance azithromycin treatment in COPD patients with frequent exacerbations. Djamin RS; Bafadhel M; Uzun S; Russell REK; Ermens AAM; Kerstens R; Aerts JGJV; Pavord ID; van der Eerden MM Respir Med; 2019; 154():27-33. PubMed ID: 31203097 [TBL] [Abstract][Full Text] [Related]
7. Predictors of chronic obstructive pulmonary disease exacerbation reduction in response to daily azithromycin therapy. Han MK; Tayob N; Murray S; Dransfield MT; Washko G; Scanlon PD; Criner GJ; Casaburi R; Connett J; Lazarus SC; Albert R; Woodruff P; Martinez FJ Am J Respir Crit Care Med; 2014 Jun; 189(12):1503-8. PubMed ID: 24779680 [TBL] [Abstract][Full Text] [Related]
8. Azithromycin and risk of COPD exacerbations in patients with and without Helicobacter pylori. Ra SW; Sze MA; Lee EC; Tam S; Oh Y; Fishbane N; Criner GJ; Woodruff PG; Lazarus SC; Albert R; Connett JE; Han MK; Martinez FJ; Aaron SD; Reed RM; Man SFP; Sin DD; Respir Res; 2017 May; 18(1):109. PubMed ID: 28558695 [TBL] [Abstract][Full Text] [Related]
9. Influence of macrolide maintenance therapy and bacterial colonisation on exacerbation frequency and progression of COPD (COLUMBUS): study protocol for a randomised controlled trial. Uzun S; Djamin RS; Kluytmans J; Van't Veer NE; Ermens AA; Pelle AJ; Mulder P; van der Eerden MM; Aerts J Trials; 2012 Jun; 13():82. PubMed ID: 22682323 [TBL] [Abstract][Full Text] [Related]
10. Prophylactic antibiotic therapy for chronic obstructive pulmonary disease (COPD). Herath SC; Poole P Cochrane Database Syst Rev; 2013 Nov; (11):CD009764. PubMed ID: 24288145 [TBL] [Abstract][Full Text] [Related]
11. A Double-Blind, Randomized, Placebo-controlled Trial of Long-Term Doxycycline Therapy on Exacerbation Rate in Patients with Stable Chronic Obstructive Pulmonary Disease. Allinson JP; Vlies BH; Brill SE; Law M; Burnside G; Finney LJ; Alves-Moreira L; Donaldson GC; Calverley PMA; Walker PP; Wedzicha JA Am J Respir Crit Care Med; 2023 Sep; 208(5):549-558. PubMed ID: 37450935 [No Abstract] [Full Text] [Related]
12. Blood eosinophils and treatment response with triple and dual combination therapy in chronic obstructive pulmonary disease: analysis of the IMPACT trial. Pascoe S; Barnes N; Brusselle G; Compton C; Criner GJ; Dransfield MT; Halpin DMG; Han MK; Hartley B; Lange P; Lettis S; Lipson DA; Lomas DA; Martinez FJ; Papi A; Roche N; van der Valk RJP; Wise R; Singh D Lancet Respir Med; 2019 Sep; 7(9):745-756. PubMed ID: 31281061 [TBL] [Abstract][Full Text] [Related]
14. Predictors of exacerbation risk and response to budesonide in patients with chronic obstructive pulmonary disease: a post-hoc analysis of three randomised trials. Bafadhel M; Peterson S; De Blas MA; Calverley PM; Rennard SI; Richter K; Fagerås M Lancet Respir Med; 2018 Feb; 6(2):117-126. PubMed ID: 29331313 [TBL] [Abstract][Full Text] [Related]
15. Eosinophil counts in first COPD hospitalizations: a comparison of health service utilization. Bélanger M; Couillard S; Courteau J; Larivée P; Poder TG; Carrier N; Girard K; Vézina FA; Vanasse A Int J Chron Obstruct Pulmon Dis; 2018; 13():3045-3054. PubMed ID: 30319252 [TBL] [Abstract][Full Text] [Related]
16. Predicting response to benralizumab in chronic obstructive pulmonary disease: analyses of GALATHEA and TERRANOVA studies. Criner GJ; Celli BR; Singh D; Agusti A; Papi A; Jison M; Makulova N; Shih VH; Brooks L; Barker P; Martin UJ; Newbold P Lancet Respir Med; 2020 Feb; 8(2):158-170. PubMed ID: 31575508 [TBL] [Abstract][Full Text] [Related]
17. Blood eosinophil count and exacerbations in severe chronic obstructive pulmonary disease after withdrawal of inhaled corticosteroids: a post-hoc analysis of the WISDOM trial. Watz H; Tetzlaff K; Wouters EF; Kirsten A; Magnussen H; Rodriguez-Roisin R; Vogelmeier C; Fabbri LM; Chanez P; Dahl R; Disse B; Finnigan H; Calverley PM Lancet Respir Med; 2016 May; 4(5):390-8. PubMed ID: 27066739 [TBL] [Abstract][Full Text] [Related]
18. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas. Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557 [TBL] [Abstract][Full Text] [Related]
19. Low-dose oral theophylline combined with inhaled corticosteroids for people with chronic obstructive pulmonary disease and high risk of exacerbations: a RCT. Devereux G; Cotton S; Fielding S; McMeekin N; Barnes PJ; Briggs A; Burns G; Chaudhuri R; Chrystyn H; Davies L; Soyza A; Gompertz S; Haughney J; Innes K; Kaniewska J; Lee A; Morice A; Norrie J; Sullivan A; Wilson A; Price D Health Technol Assess; 2019 Jul; 23(37):1-146. PubMed ID: 31343402 [TBL] [Abstract][Full Text] [Related]
20. Azithromycin for prevention of exacerbations of COPD. Albert RK; Connett J; Bailey WC; Casaburi R; Cooper JA; Criner GJ; Curtis JL; Dransfield MT; Han MK; Lazarus SC; Make B; Marchetti N; Martinez FJ; Madinger NE; McEvoy C; Niewoehner DE; Porsasz J; Price CS; Reilly J; Scanlon PD; Sciurba FC; Scharf SM; Washko GR; Woodruff PG; Anthonisen NR; N Engl J Med; 2011 Aug; 365(8):689-98. PubMed ID: 21864166 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]